20 results on '"Bouscary, Didier"'
Search Results
2. Proton Therapy Reduces the Effective Dose to Immune Cells in Mediastinal Hodgkin Lymphoma Patients
- Author
-
Loap, Pierre, De Marzi, Ludovic, Decroocq, Justine, Birsen, Rudy, Johnson, Natacha, Deau Fischer, Benedicte, Bouscary, Didier, and Kirova, Youlia
- Published
- 2024
- Full Text
- View/download PDF
3. Pediatric Plasma Cell Neoplasms: A Population-Based Study.
- Author
-
Loap, Pierre, Vignon, Marguerite, Bouscary, Didier, and Kirova, Youlia
- Published
- 2022
- Full Text
- View/download PDF
4. Relapsed, Refractory, or Advanced Hodgkin Lymphoma: A Single-Center Experience.
- Author
-
Boilève, Alice, Grignano, Eric, Bouscary, Didier, Fourquet, Alain, Deau-Fischer, Bénédicte, and Kirova, Youlia
- Published
- 2021
- Full Text
- View/download PDF
5. Paraneoplastic Hyperleukocytosis Mimicking Hematologic Malignancy Revealing a Localized Lung Cancer.
- Author
-
Marouf, Amira, Chapuis, Nicolas, Alary, Anne Sophie, Burroni, Barbara, Kosmider, Olivier, Alifano, Marco, and Bouscary, Didier
- Abstract
Paraneoplastic leukemoid reaction is a challenging differential diagnosis when it presents at the time of diagnosis of cancer. Severe hyperleukocytosis with elevation of blood neutrophils and monocytes counts can evoke myeloid hematologic malignancies. We report the case of a patient who presented with blood and bone marrow features highly suggestive of chronic myelomonocytic leukemia. The diagnosis of primary lung sarcomatoid carcinoma was performed. Surgical removal of this tumor which will always remain the priority led to full normalization of blood cell count. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. HHV-8 and multiple myeloma in France
- Author
-
Marcelin, Anne-Genevieve, Dupin, Nicolas, Bouscary, Didier, Bossi, Philippe, Cacoub, Patrice, Ravaud, Philippe, and Calvez, Vincent
- Published
- 1997
7. Danazol-induced hepatocellular adenoma
- Author
-
Fermand, Jean Paul, Levy, Yves, Bouscary, Didier, D'Agay, Marie Francoise, Clot, Philippe, Frija, Jacques, and Brouet, Jean Claude
- Subjects
Liver ,Adenoma -- Causes of ,Liver tumors -- Causes of ,Danazol -- Health aspects ,Health ,Health care industry - Abstract
The androgen steroid drug danazol is used to treat various diseases such as endometriosis, the abnormal location of endometrial tissue, which normally lines the uterus; angioneurotic edema, large areas of swelling within tissues beneath the skin, such as fat, mucous membranes, and internal organs; and idiopathic thrombocytopenic purpura (ITP), a bleeding disorder associated with a reduction in blood platelets, which are involved in clotting. Treatment with androgen steroids has been associated with various toxic effects on the liver, including impaired liver function, jaundice, and formation of liver tumors. A case is described of a 34-year-old obese woman with ITP, who was treated with danazol and developed a hepatocellular adenoma, a type of liver cell tumor. The tumor was characterized by rapid growth, large size, and internal bleeding. Danazol was withdrawn and the tumor was surgically removed. The patient recovered and her liver function returned to normal. Although danazol is a weak androgen, it causes the same adverse effects as other steroids of similar structure. The incidence of liver damage and liver tumor formation is not known for other types of anabolic steroids. It is recommended that only minimal doses of danazol be used during long-term therapy, and liver function and structure of patients on long-term danazol therapy should be routinely monitored. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1990
8. AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia.
- Author
-
Grenier, Adrien, Poulain, Laury, Mondesir, Johanna, Jacquel, Arnaud, Bosc, Claudie, Stuani, Lucille, Mouche, Sarah, Larrue, Clement, Sahal, Ambrine, Birsen, Rudy, Ghesquier, Victoria, Decroocq, Justine, Mazed, Fetta, Lambert, Mireille, Andrianteranagna, Mamy, Viollet, Benoit, Auberger, Patrick, Lane, Andrew A., Sujobert, Pierre, and Bouscary, Didier
- Abstract
AMP-activated protein kinase (AMPK) regulates the balance between cellular anabolism and catabolism dependent on energy resources to maintain proliferation and survival. Small-compound AMPK activators show anti-cancer activity in preclinical models. Using the direct AMPK activator GSK621, we show that the unfolded protein response (UPR) is activated by AMPK in acute myeloid leukemia (AML) cells. Mechanistically, the UPR effector protein kinase RNA-like ER kinase (PERK) represses oxidative phosphorylation, tricarboxylic acid (TCA) cycle, and pyrimidine biosynthesis and primes the mitochondrial membrane to apoptotic signals in an AMPK-dependent manner. Accordingly, in vitro and in vivo studies reveal synergy between the direct AMPK activator GSK621 and the Bcl-2 inhibitor venetoclax. Thus, selective AMPK-activating compounds kill AML cells by rewiring mitochondrial metabolism that primes mitochondria to apoptosis by BH3 mimetics, holding therapeutic promise in AML. [Display omitted] • Pharmacological AMPK activation by GSK621 induces unfolded protein response in AML • UPR induced by GSK621 is mainly due to PERK • AMPK/PERK activation by GSK621 induces mitochondrial apoptosis in leukemic cells • GSK621 enhances the anti-leukemic activity of venetoclax in preclinical models Grenier et al. show that pharmacological AMPK activation by GSK621 induces an unfolded protein response (UPR) that is mainly driven by PERK activation in acute myeloid leukemia (AML). AMPK/PERK activation results in mitochondrial apoptosis, and GSK621 increases the anti-leukemic activity of the Bcl-2 inhibitor venetoclax in AML preclinical models. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.
- Author
-
Trinh, Anne, Khamari, Raeeka, Fovez, Quentin, Mahon, François-Xavier, Turcq, Béatrice, Bouscary, Didier, Maboudou, Patrice, Joncquel, Marie, Coiteux, Valérie, Germain, Nicolas, Laine, William, Dekiouk, Salim, Jean-Pierre, Sandrine, Maguer-Satta, Veronique, Ghesquiere, Bart, Idziorek, Thierry, Quesnel, Bruno, Kluza, Jerome, and Marchetti, Philippe
- Abstract
Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective cure for chronic myeloid leukemia (CML) patients and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, evidence demonstrating that TKI are unable to fully eradicate dormant leukemic stem cells (LSC) indicate that new therapeutic strategies are needed to control LSC and to prevent relapse. In this study we investigated the metabolic pathways responsible for CML surviving to imatinib exposure and its potential therapeutic utility to improve the efficacy of TKI against stem-like CML cells. Using complementary cell-based techniques, metabolism was characterized in a large panel of BCR-ABL+ cell lines as well as primary CD34+ stem-like cells from CML patients exposed to TKI and L-Asparaginases. Colony forming cell (CFC) assay and flow cytometry were used to identify CML progenitor and stem like-cells. Preclinical models of leukemia dormancy were used to test the effect of treatments. Although TKI suppressed glycolysis, compensatory glutamine-dependent mitochondrial oxidation supported ATP synthesis and CML cell survival. Glutamine metabolism was inhibited by L-asparaginases such as Kidrolase or Erwinase without inducing predominant CML cell death. However, clinically relevant concentrations of TKI render CML cells susceptible to Kidrolase. The combination of TKI with Lasparaginase reactivates the intinsic apoptotic pathway leading to efficient CML cell death. Targeting glutamine metabolism with the FDA-approved drug, Kidrolase in combination with TKI that suppress glycolysis represents an effective and widely applicable therapeutic strategy for eradicating stem-like CML cells. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Sustained Leukemia-Free State and Molecular Response to Sorafenib in a Patient With Chronic Myelomonocytic Leukemia in Transformation Driven by Homozygous FLT3-ITD Malignant Hematopoiesis.
- Author
-
Kosmider, Olivier, Chapuis, Nicolas, Kaltenbach, Sophie, Coriat, Romain, Rouquette, Pascaline Boudou, Willems, Lise, Chesnais, Virginie, Radford-Weiss, Isabelle, Bardet, Valerie, Mayeux, Patrick, Tamburini, Jerome, Fontenay, Michaela, and Bouscary, Didier
- Published
- 2013
- Full Text
- View/download PDF
11. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases
- Author
-
Zompi, Simona, Tulliez, Micheline, Conti, Filoména, Leblond, Véronique, Gaulard, Philippe, Blanche, Philippe, Durand, François, Ghandi, Damaj, Dreyfus, François, Louvel, Albert, Calmus, Yvon, and Bouscary, Didier
- Published
- 2000
- Full Text
- View/download PDF
12. Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow.
- Author
-
Paubelle, Etienne, Zylbersztejn, Florence, Maciel, Thiago Trovati, Carvalho, Caroline, Mupo, Annalisa, Cheok, Meyling, Lieben, Liesbet, Sujobert, Pierre, Decroocq, Justine, Yokoyama, Akihiko, Asnafi, Vahid, Macintyre, Elizabeth, Tamburini, Jérôme, Bardet, Valérie, Castaigne, Sylvie, Preudhomme, Claude, Dombret, Hervé, Carmeliet, Geert, Bouscary, Didier, and Ginzburg, Yelena Z.
- Abstract
Vitamin D (VD) is a known differentiating agent, but the role of VD receptor (VDR) is still incompletely described in acute myeloid leukemia (AML), whose treatment is based mostly on antimitotic chemotherapy. Here, we present an unexpected role of VDR in normal hematopoiesis and in leukemogenesis. Limited VDR expression is associated with impaired myeloid progenitor differentiation and is a new prognostic factor in AML. In mice, the lack of Vdr results in increased numbers of hematopoietic and leukemia stem cells and quiescent hematopoietic stem cells. In addition, malignant transformation of Vdr
−/− cells results in myeloid differentiation block and increases self-renewal. Vdr promoter is methylated in AML as in CD34+ cells, and demethylating agents induce VDR expression. Association of VDR agonists with hypomethylating agents promotes leukemia stem cell exhaustion and decreases tumor burden in AML mouse models. Thus, Vdr functions as a regulator of stem cell homeostasis and leukemic propagation. • Transcriptional expression of VDR is associated with differentiation prognosis in AML • VDR expression is partially regulated by methylation • Combined use of hypomethylating agents and VD analog targets leukemic stem cells Paubelle et al. show that targeting the vitamin D receptor has anti-leukemic activity by acting on cell differentiation and by decreasing stemness of AML cells. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
13. The role of helical tomotherapy in the treatment of bone plasmacytoma
- Author
-
Chargari, Cyrus, Hijal, Tarek, Bouscary, Didier, Caussa, Lucas, Dendale, Remi, Zefkili, Sofia, Fourquet, Alain, and Kirova, Youlia M.
- Subjects
- *
PLASMACYTOMA , *BONE diseases , *TOMOGRAPHY , *HEALTH outcome assessment , *RADIATION dosimetry , *RADIATION doses , *COMPARATIVE studies , *PATIENTS , *THERAPEUTICS - Abstract
Abstract: We evaluated the early clinical outcome of patients with solitary bone plasmacytoma (SP) or a solitary lesion of multiple myeloma (MM) treated with helical tomotherapy (HT) compared with 3D conformal radiotherapy (3D-CRT), in terms of target coverage and exposure of critical organs. Ten patients with SP and 3 patients with a solitary lesion of MM underwent radiation therapy (RT) delivered by HT, to a dose of 40 Gy in 20 fractions. Treatment planning was then performed with 3D-CRT and the dosimetric parameters of both techniques were compared. Patients were also assessed for response to treatment and acute toxicities. With a median follow-up of 13 months, 78% of patients with pain before RT had resolution of their symptoms. Coverage of target lesion was adequate with both techniques in 12 of 13 patients. Target coverage was significantly lower for HT (V95% = 98.55% vs. 97.15%; p = 0.04, for 3D-CRT and HT, respectively). Target overdoses were also lower with HT (V105% = 2.01% vs. 0.19%; p= 0.16), although nonsignificant. Finally, there were no significant differences in organs-at-risk irradiation between both techniques. The early treatment tolerance was excellent, with no toxicity higher than grade I. RT of SP and MM with a solitary lesion can be safely delivered with HT, with no major acute side effects and good symptomatic control. Finally, HT provides a dosimetry similar to that of 3D-CRT in terms of organs-at-risk sparing and target volume coverage. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
14. Isodicentric/pseudoisodicentric chromosome 21 amplification in four cases of acute myelocytic leukemia or myelodysplasia
- Author
-
Viguié, Franck, Aboura, Azzedine, Bouscary, Didier, Guesnu, Martine, Baumelou, Elisabeth, Dreyfus, François, Casadevall, Nicole, and Tachdjian, Gérard
- Subjects
- *
MYELOID leukemia , *BONE marrow , *KARYOTYPES , *DIAGNOSIS - Abstract
The bone marrow karyotypes of three patients with acute myelocytic leukemia (AML) or myelodysplastic syndrome (MDS) were studied at diagnosis and revealed, multiple copies of the same chromosomal anomaly, considered as psu idic(21)(q22) associated with other rearrangement(s). The karyotype of a fourth patient with MDS in transformation showed one copy of a dicentric marker presumably derived from a similar psu idic(21) by (tandem?) interstitial amplification of part of its structure, resembling a “homogeneous staining region”, and described as der(21)psu idic(21)(q22)hsr(21)(q22). This rearrangement, previously described in isolated cases only, might be considered as recurrent in AML/MDS and associated with an unfavorable prognosis. It is most probably a secondary change, because it was never observed as sole abnormality and the main association, as for trisomy 21, was with del(5q). In the four cases, the number of partial supernumerary segmental 21pter→21q22 copies, ranged from 2 to 10. The AML1 gene did not appear to be the common target of this amplification because this locus had been lost by the psu idic(21) in one patient [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
15. Ophthalmic involvement of chronic lymphocytic leukemia: A systematic review of 123 cases.
- Author
-
Delestre, Florence, Blanche, Philippe, Bouayed, Emna, Bouscary, Didier, Mouthon, Luc, Brezin, Antoine, Le Jeunne, Claire, and Chaigne, Benjamin
- Subjects
- *
CHRONIC lymphocytic leukemia , *SYMPTOMS , *EYE infections , *ADNEXAL diseases , *CEREBROSPINAL fluid - Abstract
To identify clinical presentations, main causes, and prognosis of ophthalmic involvement in chronic lymphocytic leukemia (CLL), we performed a systematic review of articles describing CLL ophthalmic involvement in January 2019, using the PubMed database. We found 86 articles describing 123 cases of patients with ophthalmic involvement associated with CLL. Ophthalmic symptoms were CLL's first manifestation in 25.6% of patients and revealed Richter transformation in 11.0%. There were three main causes of ophthalmic features: CLL-infiltration (52.0%), lymphoma (26.0%), and infection (15.4%), with specific clinical and radiological characteristics. CLL-infiltration was mostly bilateral, whereas lymphoma was usually unilateral (P = 0.02). Optic neuropathy was always secondary to CLL-infiltration, and in those cases, cerebrospinal fluid immunophenotyping was a potential alternative to invasive biopsy as it confirmed the diagnosis in 4 patients (36.4%). On the contrary, lymphoma usually presented as adnexal involvement (P = 0.04), particularly as an orbital mass (P = 0.004). Infections concerned mostly patients previously treated for CLL (P < 0.0001), and main presentations included posterior uveitis (P = 0.0002) and retinal infiltrates (P < 0.0001). Overall, the prognosis was poor, as 29.3% of the patients died within 36 months of follow-up, and 26.1% had a partial or total visual loss. Eye infections were associated with the poorest prognosis as 47% of patients died, with a 6-month-median survival. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Solitary Plasmacytoma Treated by Lenalidomide-Dexamethasone in Combination with Radiation Therapy: Clinical Outcomes.
- Author
-
Mignot, Fabien, Schernberg, Antoine, Arsène-Henry, Alexandre, Vignon, Marguerite, Bouscary, Didier, and Kirova, Youlia
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *SURVIVAL , *COMBINATION drug therapy , *DEXAMETHASONE , *PLASMACYTOMA , *PROGNOSIS , *RADIOTHERAPY , *MULTIPLE myeloma - Abstract
Purpose: The study evaluates the results of the concurrent use of lenalidomide-dexamethasone with intensity modulated radiation therapy (IMRT) for solitary plasmacytoma in terms of toxicity and outcome.Methods and Materials: Forty-six patients were treated for histologically proven solitary plasmacytoma (SP) between June 2007 and June 2018 in our Department (Curie Institute, Paris, France). All patients received IMRT. The median total dose was 40 Gy (range, 40-46). Prescription of concurrent lenalidomide-dexamethasone with radiation therapy was left to the discretion of the referring hematologist-oncologist and started the first day of radiation therapy for 4 cycles.Results: Twenty-seven solitary plasmacytoma were treated with IMRT alone and 19 with lenalidomide-dexamethasone in association with IMRT. At 5 years, the local control, multiple myeloma-free survival (MMFS), and progression-free survival (PFS) rates were 96.3%, 85.4%, and 60%. MMFS and PFS were significantly higher in the IMRT plus lenalidomide-dexamethasone group compared with IMRT alone group (100% vs 77.1%, P = .02 and 81.7% vs 48.4%, P = .047, respectively). No major toxicity was found in either group.Conclusions: Lenalidomide-dexamethasone in association with IMRT in the treatment of solitary plasmacytoma is safe and improves MMFS and PFS. Further prospective and comparative studies are needed to confirm these results. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
17. Azacitidine for the treatment of relapsed and refractory AML in older patients.
- Author
-
Itzykson, Raphael, Thépot, Sylvain, Berthon, Céline, Delaunay, Jacques, Bouscary, Didier, Cluzeau, Thomas, Turlure, Pascal, Prébet, Thomas, Dartigeas, Caroline, Marolleau, Jean-Pierre, Recher, Christian, Plantier, Isabelle, Stamatoullas, Aspasia, Devidas, Alain, Taksin, Anne-Laure, Guièze, Romain, Caillot, Denis, Vey, Norbert, Adès, Lionel, and Ifrah, Norbert
- Subjects
- *
ACUTE myeloid leukemia treatment , *AZACITIDINE , *CANCER relapse , *DISEASES in older people , *CANCER chemotherapy , *HUMAN cytogenetics , *HEALTH outcome assessment - Abstract
The prognosis of patients older than 50 with relapsed or refractory AML is dismal. Azacitidine has been investigated in older AML patients. Here we report the outcome of 130 patients older than 50 years included in a multicenter patient named program of azacitidine after relapse ( n = 67) or induction failure ( n = 63) of intensive chemotherapy. Median age was 67 years, cytogenetic risk was high in 28% and performance status ≥2 in 15% of cases. Most (72%) patients received azacitidine at the standard schedule (75 mg/m 2 /d, 7 days/month) for a median of 4 courses. The overall response rate was 17% (CR: 10%, CRi: 7%). Median overall survival was 8.4 months. Achievement of CR/CRi was associated with prolonged survival ( P = 0.0001), whereas hematological improvement according to MDS criteria, achieved in 36% of patients with resistant disease, did not improve survival. In multivariate analysis, high risk cytogenetics ( P = 0.022) and peripheral blasts >10% ( P < 0.0001) at onset of azacitidine were independently predictive of poor prognosis. Combining these two factors, we identified a subgroup of 48% of patients with intermediate risk cytogenetics and peripheral blasts ≤10% and a median OS of 11.3 months. These results warrant further investigation of azacitidine-based regimens in this subgroup of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Place of modern imaging modalities for solitary plasmacytoma: Toward improved primary staging and treatment monitoring
- Author
-
Chargari, Cyrus, Vennarini, Sabine, Servois, Vincent, Bonardel, Gerald, Lahutte, Marion, Fourquet, Alain, Bouscary, Didier, and Kirova, Youlia M.
- Subjects
- *
PLASMACYTOMA , *CANCER radiotherapy , *RADIOSCOPIC diagnosis , *MAGNETIC resonance imaging , *POSITRON emission tomography , *CANCER prognosis , *THERAPEUTICS - Abstract
Abstract: Radiation therapy (RT) is the mainstay of treatment of solitary plasmacytoma. In most cases, doses ranging from 40 to 50Gy yield in a local control more than 80%. However, the prognosis of patients with SP is marked by a high rate of transformation to multiple myeloma (MM), and there is no demonstrated benefit of adjuvant chemotherapy for decreasing this probability. However, clinical benefits could be reached from improving screening for other primary sites of plasmacytoma and earlier discovering signs suggestive of MM. Since such strategy could provide significant information regarding both prognosis and therapy, it has become first importance to improve initial staging of tumor widespread. Although conventional skeletal X-ray survey remains standard, usual sensitivity of radiographies does not permit diagnosing early myeloma lesions and a significant number of patients with supposed SP might be understaged and do not receive the appropriate treatment. The development of more sensitive and specific imaging modalities will make it feasible to earlier detect subclinical lesions, thus leading lead to new approaches in the treatment strategies. Here, we discuss the benefits and limitations of magnetic resonance imaging and positron emission tomography for primary staging of patients with solitary plasmacytoma. Both imaging modalities could also improve target volume delineation and assessment of tumor response after RT. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
19. When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group)
- Author
-
Cassinat, Bruno, de Botton, Stéphane, Kelaidi, Charikleia, Ades, Lionel, Zassadowski, Fabien, Guillemot, Isabelle, Schlageter, Marie-Helene, Raffoux, Emmanuel, Harousseau, Jean-Luc, Legrand, Olivier, Escoffre-Barbe, Martine, Reman, Oumedaly, Gardembas, Martine, Himberlin, Chantal, Cahn, Jean Yves, Guyotat, Denis, Bouscary, Didier, Parry, Anne, Rousselot, Philippe, and Baruchel, Andre
- Subjects
- *
DIAGNOSTIC use of polymerase chain reaction , *CANCER relapse , *ACUTE myeloid leukemia , *MESSENGER RNA , *HEMATOLOGY , *COHORT analysis , *PATIENTS - Abstract
Abstract: 10–20% of APL patients relapse and the challenge remains to early identify these patients to improve survival rate. We report PML-RARα transcript detection by RQ-PCR in 260 consecutive APL patients (n =970 samples). 223 patients with samples of sufficient RNA quality to demonstrate they reached molecular remission were monitored for MRD. During follow-up, 38 of these patients were tested positive for PML-RARα mRNA. 13 out of the 38 patients (34%) effectively developed hematological relapse. In the first positive sample, specific PML-RARα NCN thresholds over which, or under which, patients could effectively be predicted to relapse or not, were identified and subsequently validated in a second cohort. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
20. IgA monoclonal gammopathy associated with refractory IgA vasculitis successfully treated with clone-targeted therapy.
- Author
-
Paule, Romain, Vignon, Marguerite, Régent, Alexis, London, Jonathan, Cohen, Pascal, Le Jeunne, Claire, Mouthon, Luc, Bouscary, Didier, Tamburini, Jérôme, and Terrier, Benjamin
- Subjects
- *
MONOCLONAL gammopathies , *VASCULITIS , *PLASMA cell diseases , *LEUKOCYTOCLASTIC vasculitis - Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.